CVS Caremark CVS announces its next round of earnings this Thursday, November 3, 2011. Get the latest predictions in Benzinga's essential guide to the company's third quarter earnings report.
Earnings and Revenue:
Here's how the company's reported EPS has stacked up against analyst estimates in the past:
Quarter | Q2 | Q1 | Q4 | Q3 |
EPS Estimate | $0.64 | $0.55 | $0.79 | $0.64 |
EPS Actual | $0.65 | $0.57 | $0.80 | $0.65 |
Stock Performance:
- Long-term shareholders are already enjoying 12-month gains prior to the announcement
Average Stock Rating:
Competitors:
- BioScrip BIOS: Moderate Buy with a $0.10 recent quarter EPS
- GNC Holdings GNC: Moderate Buy with a $0.46 recent quarter EPS
CVS Caremark is in the retail-drug stores industry, which has experienced price/earnings growth of 1.5%.
Finally, a description of the company's main areas of operation: CVS Caremark provides prescriptions and related health care services and products.
Take Action:
Now that you're fully prepared, get ready to take quick action if the company reports any numbers significantly different from those listed above. Also, check back in with us after the announcement for a full recap and what-to-do-next guide.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.